NVN Liquidation (NVN Liquidation) Debt-to-Asset : 0.05 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation Debt-to-Asset?

NVN Liquidation's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.47 Mil. NVN Liquidation's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $3.39 Mil. NVN Liquidation's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2023 was $79.79 Mil. NVN Liquidation's debt to asset for the quarter that ended in Mar. 2023 was 0.05.

NVN Liquidation Debt-to-Asset Historical Data

The historical data trend for NVN Liquidation's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation Debt-to-Asset Chart

NVN Liquidation Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.30

0.22

0.02

0.05

0.04

NVN Liquidation Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Asset	Get a 7-Day Free Trial															0.18	0.18	0.05	0.04	0.05

Competitive Comparison of NVN Liquidation's Debt-to-Asset

For the Biotechnology subindustry, NVN Liquidation's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NVN Liquidation's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NVN Liquidation's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NVN Liquidation's Debt-to-Asset falls into.

NVN Liquidation Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NVN Liquidation's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.191	+	3.739)	/	90.33
	=	0.04

NVN Liquidation's Debt-to-Asset for the quarter that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.465	+	3.387)	/	79.793
	=	0.05

NVN Liquidation (OTCPK:NOVNQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NVN Liquidation Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NVN Liquidation (NVN Liquidation) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman	director	9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour	director	C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay	officer: VP, Finance & Corp. Controller	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John	officer: EVP, Chief Operating Officer	C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky	director	TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin	director	C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram	director	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer	director	7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak	officer: Chief Accounting Officer	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker	10 percent owner	100 SAS CAMPUS DRIVE, CARY NC 27513